2. Cell Cycle/DNA Damage Apoptosis Metabolic Enzyme/Protease Immunology/Inflammation NF-κB
  3. Topoisomerase Apoptosis Reactive Oxygen Species
  4. 2982740-97-4

2982740-97-4

Pirenzepine-d<sub>8</sub> dihydrochloride Chemical Structure

2982740-97-4

Chemical Structure

  • Pirenzepine-d8 dihydrochloride
  • Synonym(s): LS 519-d8 dihydrochloride;Pirenzepin-d8 dihydrochloride;Gastrozepin-d8 dihydrochloride
  • CAS No: 2982740-97-4
    Formula: C19H15D8Cl2N5O2
    Molecular Weight: 432.37
  • InChIKey: FFNMBRCFFADNAO-OSNULJQWSA-N
  • SMILES: O=C1NC2=CC=CN=C2N(C(CN3C([2H])([2H])C([2H])([2H])N(C)C([2H])([2H])C3([2H])[2H])=O)C4=CC=CC=C14.Cl.Cl

Biological Activity: Pirenzepine-d8 (LS 519-d8; Pirenzepin-d8) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells[1][2][3].

Cat. No. Product Name Purity Description
HY-170126 CRBN ligand-74 CRBN ligand-74 is a CRBN-type E3 ubiquitin ligase ligand that can be used to prepare PROTAC.

References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246. [Content Brief]
[2]. Carmine AA, et al. Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs. 1985 Aug;30(2):85-126. [Content Brief]
[3]. Yin QQ, et al. Muscarinic acetylcholine receptor M1 mediates prostate cancer cell migration and invasion through hedgehog signaling. Asian J Androl. 2018 Nov-Dec;20(6):608-614. [Content Brief]

Keywords:

Pirenzepine-d8 dihydrochloridePirenzepine-d8Pirenzepine dihydrochloridePirenzepine (dihydrochloride) (Standard)